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Abstract  
The American Society for Bone and Mineral Research and the United States National Osteoporosis 
Foundation (NOF) formed a working group to develop principles of goal-directed treatment and 
identify gaps that need to be filled to implement this approach. With goal-directed treatment, a 
treatment goal would first be established choice of treatment determined by the probability of achieving 
that goal. Goals of treatment would be freedom from fracture, a T-score > -2.5, which is above the 
NOF threshold for initiating treatment, or achievement of an estimated risk level below the threshold 
for initiating treatment.  Progress toward reaching the SDWLHQW¶Vgoal would be periodically and 
systematically assessed E\HVWLPDWLQJWKHSDWLHQW¶VFRPSOLDQFHZLWKWUHDWPHQWUHYLHwing fracture 
history, repeating vertebral imaging when indicated, and repeating measurement of bone mineral 
density (BMD).  Using these data, a decision would be made to stop, continue, or change therapy. 
Some of these approaches can now be applied to clinical practice. However, the application of goal-
directed treatment cannot be fully achieved until medications are available that provide greater 
increases in BMD and greater reduction in fracture risk than those that are currently approved; only 
then can patients with very high fracture risk and very low BMD achieve such goals. Furthermore, 
assessing future fracture risk in patients on treatment requires a new assessment tool that accurately 
captures the change in fracture risk associated with treatment and should also be sensitive to the 
importance of recent fractures as predictors of imminent fracture risk. Lastly, evidence is needed to 
confirm that selecting and switching treatments to achieve goals reduces fracture risk more effectively 
than current standard care. This article is protected by copyright. All rights reserved 
 
Keywords: osteoporosis, treatment, goal, target, treat-to-target, treat-to-goal 
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Background  
It has been proposed that the goal of treatment for osteoporosis should be an acceptably low risk of 
fracture and that treatment decisions should be guided by maximizing the probability that a patient will 
achieve the goal.(1,2) The American Society for Bone and Mineral Research (ASBMR) and the United 
States National Osteoporosis Foundation (NOF) established the Working Group on µGoal-directed 
Treatment for Osteoporosis¶ to consider setting goals to guide therapeutic decisions. The Working 
Group members were selected for their expertise and clinical experience in the management of 
osteoporosis.  They represent a broad array of primary care and specialist clinicians and experts in 
epidemiology and ethics from the United States, Canada, Europe, Australia/New Zealand, and Japan. 
Many are also members or leaders of other societies that focus on osteoporosis. The Working Group 
includes no representatives and received no funding from the pharmaceutical industry. Some members 
of the Working Group have received funds from pharmaceutical companies as described in the 
disclosures. 
After several discussions of draft principles, the Working Group concluded that setting 
treatment goals with patients and making therapeutic decisions based on the likelihood of achieving 
those goals is an ideal strategy for treatment of osteoporosis.  Some parts of this approach can be 
recommended for use in clinical practice now.  Other components have limitations that need to be 
addressed before implementation in clinical practice. In particular, there is a need for new treatments 
that have more potent effects on fracture risk and bone mineral density (BMD) that would enable 
patients to achieve goals that may not be reachable with current therapies.  Ideally, additional agents 
that act to maintain treatment targets (beyond intermittent bisphosphonates) are also needed to optimize 
the goal- directed treatment paradigm. 
There is limited evidence on which to base principles of goal-directed treatment. This report 
describes principles based on interpretation of evidence that reflects a consensus of expert opinion of 
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members of the Working Group. The report represents the first step of an iterative process that warrants 
continued discussion. Gaps in evidence need to be filled so that treatment decisions based on goals are 
grounded in sufficient data. 
 
Differences between standard treatment and goal-directed treatment 
With current guidelines for managing osteoporosis, once a decision has been made to treat a patient 
with a pharmacologic agent, a ³first line´ drug, usually an oral bisphosphonate, is prescribed. BMD is 
often repeated 1-2 years later to evaluate for response to therapy. Stabilization or improvement of BMD 
is usually accepted as validation that the patient is responding appropriately to treatment. The same 
treatment is then continued; after 3-5 years of oral or intravenous bisphosphonate therapy, a 
ELVSKRVSKRQDWH³KROLGD\´ may be considered.(3) If there is a statistically significant decline in BMD 1-
2 years after starting therapy, clinicians may evaluate for factors contributing to a suboptimal response 
to therapy and consider switching to a different agent. Sometimes bone turnover markers are used to 
monitor response to therapy, with a significant change in the expected direction (decreased with 
antiresorptive agents, increased with osteoanabolic agents) taken as an acceptable response. 
In contrast, goal-directed treatment is a strategy where (a) a goal of treatment is established for 
a patient, (b) the initial choice of treatment is based on the probability of reaching the goal, and (c) 
progress toward reaching thHSDWLHQW¶VJRDO is reassessed periodically, with decisions to stop, continue, 
or change treatment based on achievement of the goal or progress toward achievement of the goal. 
Goal-directed treatment differs from standard practice in a fundamental way.  As with all treatment, the 
overriding goal of treatment is to achieve freedom from fracture or at least a low risk of fracture. If a 
fracture, including a morphometric vertebral fracture, occurs during treatment, despite evidence of 
response to treatment by improvement in BMD and markers of bone turnover, then the patient has an 
increased risk of a recurrent fracture for at least several years (4-6), warranting consideration of 
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switching to a more potent treatment or combination of treatments or, at a minimum, continuing an 
effective therapy.   
 
Principles of Goal-directed treatment 
1. Establishing treatment goals 
The principles of goal-directed treatment are founded on the identification of a target BMD or 
fracture risk to guide decisions about initial treatment and treatment decisions during the course of 
therapy. Currently, the NOF suggests initiating treatment in patients with hip or vertebral fractures, 
patients with a T-score in the lumbar spine, total hip or femoral neck  -2.5, and those with a 10-year 
probability of hip fracture 3% or 10-year probability of major osteoporotic fracture , using the 
US-adapted World Health Organization (WHO) absolute fracture risk model (FRAX®).(7) 
Osteoporosis treatment goals parallel indications for initiating treatment; logical treatment goals are 
BMD levels above and fracture risk levels below those for which treatment is usually recommended. In 
a patient with an incident fracture while on osteoporosis medication, treatment should be continued 
regardless of the T-score, since the risk of another fracture in the next few years is very high.(4-6) Once 
a fracture-free interval of 3-5 years has been documented, other treatment targets can be considered, as 
follows. 
  
T-score as a goal. If the primary reason for starting treatment is a T-score  -2.5 at the femoral 
neck, total hip, or lumbar spine by dual-energy X-ray absorptiometry (DXA), then the goal of treatment 
is a T-score > -2.5 at that skeletal site. Although absolute BMD (in g/cm2) is used for quantitative 
comparison of serial BMD measurements by DXA, T-score is preferred as a goal because T-scores 
mitigate much of the BMD variability associated with different skeletal sites, regions of interest, and 
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DXA make and model. This approach is feasible in clinical practice.  A T-score goal is attractive 
because it is measurable and improved by treatments.  
There is limited evidence that, for an individual patient, greater increases in BMD are 
associated with greater reductions in fracture risk.  Previous meta-analyses(8) and a preliminary report 
from a meta-analysis of almost all trials of anti-resorptive drugs done up to 2015(9)  found that for 
individual patients, there was only weak correlations between change in femoral neck BMD on 
treatment and change in risk of nonvertebral fracture. In contrast, decreases in spine BMD during 
treatment with alendronate has been associated with a higher risk of vertebral fracture than in those 
whose spine BMD improved(10) Changes in femoral neck BMD in individual patients during 3 years 
of treatment with denosumab were correlated with reductions in risk of nonvertebral fracture.(11) On 
the other hand, for the purpose of predicting of the results of clinical trials of antiresorptive drugs, 
greater increases in mean vertebral and femoral neck BMD in trials of antiresorptives are significantly 
associated with greater of reductions in the risk of vertebral and hip fractures, respectively, in those 
trials.(8) (12) (9)  
Of greater importance than the association between BMD gain and fracture risk reduction, 
however, is identification of a T-score value above which there is an acceptably low risk of future 
fracture. Evidence from the Fracture Intervention Trial Long-term Extension (FLEX) trial of 
alendronate and the HORIZON Extension trial of zoledronic acid indicate that a persistently low 
femoral neck T-VFRUH-2.5 in women who had received 5 years of treatment with alendronate or 3 
years of zoledronic acid was associated with a high risk of future vertebral fracture.(4,13,14).  
Furthermore, in a post hoc analysis of a high risk subset of subjects in the FLEX trial, continuing 
alendronate beyond 5 years reduced the risk of nonvertebral fractures in women with femoral neck T-
VFRUH -2.5, but not in those with a femoral neck T-score > -2.5.(15) With continued zoledronic acid 
treatment beyond 3 years, there was a suggestion that continued vertebral fracture risk reduction was 
limited to those with T-sFRUH-2.5, with the absolute risk of fracture very low in those patients who 
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attained BMD above that level.(4) Similarly, data from the FREEDOM Extension study of denosumab 
also suggest that fracture risk while on denosumab treatment is a function of the hip T-score achieved 
during treatment.(16) A target T-score > -2.5 is also consistent with the recommendations of the 
ASBMR Working Group on Long-term Bisphosphonate Treatment,(3) which state that after treatment 
for 5 years with alendronate or 3 years with zoledronic acid, postmenopausal women with low fracture 
risk (hip T-score > ±2.5) may be considered for discontinuation of bisphosphonate therapy, with 
reassessment of fracture risk 2 to 3 years after discontinuation.   
There are a number of limitations to the use of T-score as a target for osteoporosis treatment. 
For some skeletal sites, such as the femoral neck, achieving a goal T-score > -2.5 might be unlikely or 
impossible with current medications. There are no data about continued benefits of treatment or risk of 
future fracture for lumbar spine BMD. A clinician might decide to set a goal of T-score > -2.5 at the 
lumbar spine because of discordance in BMD between the lumbar spine and hip, with a lower spine 
BMD indicating a greater risk of vertebral fracture.(17,18) A lumbar spine T-score goal may be 
particularly important when the treatment being considered, such as teriparatide, improves spine BMD 
substantially more than hip BMD. Measurement of BMD, as with any measurement, has inherent 
variability due to factors that include instrument calibration, patient positioning, and analysis.  
Furthermore, lumbar spine BMD in the elderly may increase due to degenerative changes that are not 
associated with improvement in bone strength. For individual patients, serial BMD measurements by 
DXA typically KDYHD³OHDVWVLJQLILFDQWFKDQJH´in the range of 3-5% (about 0.3 to 0.5 T-score units) 
with a 95% level of confidence.(4) Therefore, reaching a T-score > -2.0 on a single measurement 
provides a very high degree of confidence that the T-score is truly > -2.5.  Confidence that the goal T-
score > -2.5 has been achieved is also enhanced when the T-score at a skeletal site is > -2.5 on more 
than one measurement. In consideration of technical differences with DXA systems of different 
manufacturers and sources of measurement variability, measurements should ideally be made on the 
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same device at the same facility, using the same reference databases to calculate T-scores, provided 
there is adherence to well-established quality standards(19) and DXA Best Practices.(20) With future 
advances in knowledge, other methods for assessing bone strength, such as finite element analysis, may 
someday play a role in determining treatment targets.  
 
Fracture risk as a goal.   If the primary reason for starting treatment is a high absolute risk of 
fracture, then the goal is a level of fracture risk below the risk threshold for initiating treatment. For 
example, if the treatment threshold were a 10-year risk of major osteoporotic fractures (hip, humerus, 
ZULVWDQGFOLQLFDOVSLQHIUDFWXUHVWKHQWKHWUHDWPHQWJRDOwould be a 10-year risk below 20%. 
$SDWLHQW¶VULVNRIIUDFture will, on average, decrease by the amount observed in clinical trials in a 
patient who is adherent to therapy. For example, a patient with a 5% 10-year risk of hip fracture will 
reduce that risk to about 3% by treatment with an agent that reduces hip fracture risk by 40%. However, 
using fracture risk as a goal of therapy for individual patients is limited by the absence of a validated 
approach for estimating the risk of fractures in individual patients who are receiving treatment.(21) 
Observational studies have found that the World Health Organization fracture risk assessment tool 
(FRAX) is not sensitive enough to the changes in BMD and fracture risk with treatment, with fracture 
probabilities tending to increase because of increasing age during treatment.(22,23). In addition, FRAX 
fracture risk calculations do not take into account how recently a fracture occurred.  Recent clinical 
trial and observational data in individuals treated for osteoporosis suggest that a history of recent 
fracture during treatment is associated with an increased risk of another fracture during treatment.(4-6) 
Despite its logical appeal as a treatment goal, fracture risk is currently not feasible for clinical practice. 
Better methods for assessing fracture risk for patients on treatment are needed in order to enable use of 
fracture risk goals to guide therapeutic decisions. 
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2. Goal-directed selection of initial therapy  
The Working Group recognizes that selection of treatment is often based on, or constrained by, local 
policies and payer reimbursement practices.  Furthermore, selection of therapy must consider patient 
age, stage of life, comorbidities, concomitant medications, falling risk and frailty, in addition to 
severity of osteoporosis.  
 For patients with recent fractures, it is critical to prevent fractures during the next several years, 
when the risk of another fracture is substantially elevated.(24-31) Therapeutic agents that reduce 
fracture risk rapidly are desirable for these patients.   
 For patients with a T-score substantially below -2.5, treatments having the potential to achieve a 
greater increase in BMD should be considered. The acceptable probability of achieving the treatment 
goal and the time to achieve it has not been established.  Defining this probability requires analyses of 
the costs and benefits of alternative approaches. In the absence of such evidence, the Working Group 
judged that it was intuitively reasonable to expect that initial treatment should offer at least a 50% 
chance of achieving the treatment goal within 3 to 5 years of starting therapy. This level of probability 
has not been generated from trials of approved drugs and should be revised if evidence suggests that an 
alternative probability is more appropriate. 
If initial treatment with an oral bisphosphonate offers a low probability of reaching the target T-
score of > -2.5, then an agent with substantially greater effect on BMD, if available, should be 
considered for initial therapy.  Similarly, if initial treatment with an oral bisphosphonate offers a low 
probability that the patient will reach a goal of reduction in fracture risk, an agent or sequence or 
combination of agents with greater effect on fracture risk should be considered for initial therapy. 
Choice of initial therapy should also consider the balance of expected benefits and potential risks, 
patient preference, and cost.  This approach is feasible to apply to clinical practice currently. 
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Screening for vertebral fracture.  Patients who have sufficiently high risk of fracture or low 
BMD to warrant starting treatment should have DXA-based vertebral fracture assessment (VFA), or a 
lateral thoracolumbar spine radiograph to determine whether vertebral fractures are present. This 
principle is based on the recommendation from the NOF and the International Society for Clinical 
Densitometry which state that women age  70 years and men age  80 years should have a screening 
vertebral imaging test if the T-score is  -1.0 at the lumbar spine, femoral neck, or total hip; women age 
65-69 years and men age 70-79 years should have vertebral imaging if the T-score is -1.5 at any of 
these skeletal sites.(7,19) The presence of a vertebral fracture, especially one that is at least of moderate 
severity and/or a recent occurrence, greatly increases fracture risk and may warrant selection of an 
initial treatment that has the greatest efficacy for reducing the risk of vertebral fracture. Additionally, 
obtaining a baseline spine image allows for comparison with repeat spine imaging in the future to 
determine whether a vertebral fracture has occurred during therapy; this information might influence 
subsequent treatment decisions to intensify and/or continue treatment.  The Working Group noted that 
the use of vertebral imaging might differ in different countries and that recommendations about 
vertebral imaging should consider local guidelines.  Measuring body height accurately when treatment 
starts also allows for assessment of height change during treatment follow-up that helps inform 
decisions about when to obtain a follow-up VFA or spine radiograph. 
 
3. Goal-directed assessments and treatment decisions during treatment 
Assessing adherence to treatment.  Achieving a goal requires adherence to treatment. In 
general, taking less than 80% of prescribed oral medications is associated with a suboptimal therapeutic 
effect, which may be recognized by a decline in BMD, failure of bone turnover markers to respond as 
expected, or occurrence of a fracture. Poor adherence should prompt interventions to improve 
adherence.(32) The Working Group suggests that when adherence to an oral agent is inadequate, 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved 12 
parenteral therapy should be considered. Levels of adherence with pill taking may be difficult to 
estimate in practice but can be approximated from electronic pharmacy records, if available, using the 
history of patient refills of prescribed therapy. Comparisons of adherence with oral and injectable 
therapy showed that treatment with SC denosumab every 6 months (33) and IV ibandronate every 3 
months (34) produced better adherence than did weekly oral bisphosphonate.  
Monitoring response to therapy. A treatment goal cannot be achieved unless the patient is 
responding to therapy, although response to therapy is not a guarantee that the goal will be reached.  A 
fracture occurring while on therapy warrants further evaluation to confirm no hidden underlying 
secondary causes of osteoporosis. Patients who have had fractures on treatment should not be 
considered to have achieved treatment goals until they have remained free of fracture for at least 3-5 
years past the fracture. Guidelines recommend repeating a DXA study 1 to 2 years after starting 
therapy, and/or measuring a bone turnover marker(7,35) to assure that there is a treatment response.  
However, a patient may be a good responder with improvement in BMD or an appropriate change in 
bone turnover marker, yet still have an unacceptably high level of fracture risk.  This could be because 
BMD remains very low, the patient had a recent fracture or there are underlying comorbidities or 
medications that increase fracture risk substantially. With the goal-directed approach, despite a 
treatment response being confirmed, consideration should be given to modifying therapy to help 
achieve treatment goals. 
Patients whose BMD does not improve on treatment cannot achieve a T-score goal. Loss of 
BMD during treatment warrants evaluation of adherence and other causes of inadequate response to 
treatment.(7,19,35) Treatment monitoring should also include assessment of possible adverse effects of 
therapy, interval fracture history, assessment of back pain, and body height measurement to determine 
whether VFA should be repeated.(36)  
There have been no analyses of the best frequency for reassessing fracture history, re-screening 
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for vertebral fractures, or measuring height. Furthermore, the ideal interval for assessing BMD has not 
EHHQVWXGLHGDQGZRXOGGHSHQGRQWKHGLIIHUHQFHEHWZHHQWKHSDWLHQW¶VT-score and T-score goal and 
expected effects of the treatment.  However, the Working Group judged that, in general, it would be 
reasonable to reassess patients yearly for assessment of adherence, interval medical history and height 
measurement, and at least every 2 to 3 years to determine whether the goal has been achieved or if 
there is a high likelihood that it will be achieved soon.  Timely achievement of the treatment goal is 
desirable, although there is no analysis indicating an acceptable duration of treatment to achieve the 
goal.  It is rational to utilize the medication most likely to achieve the BMD goal quickly in patients at 
highest risk for fracture.   
 
Assessment of treated patients should include several elements: 
Assessment for occurrence of new vertebral fracture. If a new vertebral fracture occurs, whether 
it be a clinically apparent or radiographic fracture found by proactive vertebral imaging, continuation 
of treatment for up to 5 additional years should be considered, after appropriate evaluation for factors 
contributing to skeletal fragility, regardless of evidence of achievement of a T-score goal. The patient 
should be treated with an agent that maximizes the prevention of another vertebral fracture. Occurrence 
of back pain consistent with an acute vertebral fracture warrants clinical evaluation and imaging.   If 
height was measured at baseline, then it should be measured again at follow-up visits at least after 3-5 
years of treatment to screen for asymptomatic new vertebral fracture.  More than a 2 cm (> ¾ inch) 
decrease in measured height indicates an increased probability that a new vertebral fracture has 
occurred and warrants spine imaging with repeat VFA or radiography.(36,37) For the same reasons, if 
height and spine imaging were not obtained at baseline, they should be considered early during 
treatment.  These principles are based primarily on expert opinion and warrant additional analysis of 
the cost and benefits of this approach. 
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Occurrence of nonvertebral fracture during treatment. With a recent nonvertebral fracture, 
continuation of treatment or changing to one with greater efficacy for reducing nonvertebral fracture 
risk should be considered, after appropriate evaluation for factors contributing to skeletal fragility, 
regardless of achievement of a T-score goal. Current treatments typically reduce the risk of 
nonvertebral fractures by about 20-35% during 1.5-5 years of treatment.(38) It is not clear that 
switching treatment will offer additional reduction in risk of nonvertebral fracture. (4,39-44) Based on 
studies from patients who are not receiving treatment, the increase in risk of fracture associated with an 
incident nonvertebral fracture may be greatest in the first 5 years after the fracture occurs and then 
wane with time.(24-31) Furthermore, in patients receiving zoledronic acid, incident nonvertebral 
fracture is an important risk factor for future nonvertebral fractures over the next three years if therapy 
is discontinued.(4) Therefore, it is the opinion of the Working Group that the occurrence of a 
nonvertebral fracture during treatment, even if the T-score goal has been reached, should prompt 
continuation, change or addition of therapy, at least until the patient has been fracture-free for 3 to 5 
years.  Evidence is needed to confirm that this approach will reduce the risk of subsequent nonvertebral 
fractures. 
Change in other risk factors for fracture risk on treatment. Besides occurrence of fracture on 
treatment, changes in other risk factors for fracture, such as change in medications, weight loss, or 
development of a diagnosis that influences fracture risk suggests a change in risk of fracture during 
treatment. These changes may influence the decision to continue or switch to a more potent agent. This 
view is based on expert opinion and requires the development of models that accurately estimate risk of 
fracture during treatment. 
Achievement of a T-score goal. Other groups have made recommendations about stopping or 
continuing treatment after achieving T-score levels.(3,45) If a decision is made to stop treatment, goal-
directed treatment suggests that BMD should be maintained above the goal (i.e., generally a T-score > -
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2.5). Based on randomized trials comparing the benefits of continuing alendronate or zoledronic acid 
versus stopping treatment, the benefits of continuing treatment appear to be very small when the patient 
has achieved a femoral neck T-score > -2.5. (45). However, tKHFRQFHSWRID³GUXJKROLGD\´DSSOLHV
only to patients taking bisphosphonates because of a transient residual antiresorptive effect after 
discontinuation due to skeletal retention of drug. For non-bisphosphonates, a drug holiday is not 
appropriate, since BMD declines rapidly after treatment is stopped.(46,47) Therefore, after a T-score 
goal is achieved with a non-bisphosphonate, treatment should generally be continued with an agent that 
maintains BMD, possibly a bisphosphonate (at least short-term).(33) Additional medications that can 
maintain treatment effects after achieving treatment goals would enhance the goal-directed treatment 
strategy. Although there are no data about the efficacy of this strategy, the Working Group judged that 
it is reasonable to consider restarting treatment if a fracture occurs, a SDWLHQW¶V%0'at the hip or spine 
decreases, or risk of fracture increases to a level that would warrant initiation of treatment (e.g., the use 
of glucocorticoids or new parental history of hip fracture).  $SDWLHQW¶VULVNRIIUDFWXUHULVHVZLWKDJH
and may reach a level that warrants resumption of pharmacologic therapy even in the absence of other 
factors. The best interval for repeating measurements of BMD has not been determined. Measurement 
of markers of bone turnover might aid decisions about resuming treatment, but the Working Group did 
not address targets for bone turnover markers due to limited evidence and uncertainties with these 
measurements.  
 
Limitations of goal-directed treatment 
Although several principles of goal-directed therapy could be applied to clinical practice, the concept 
has limitations.(48) In particular, it may not be feasible for patients with a very high risk of fracture or 
very low BMD to achieve goals with current treatments; more potent treatments are needed. For 
example, with current treatments it may not be possible for a patient with a very high baseline risk of 
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fracture, such as a 10% ten-year probability of hip fracture, to reduce that risk to < 3%, or for a patient 
with a baseline femoral neck T-score of -3.5 to achieve a T-score > -2.5. For these patients, treatment 
with the most potent agents should be considered. Optimal treatment sequences, such as anabolic 
therapy followed by a potent antiresorptive drug, could potentially achieve BMD goals (even in 
patients who start with very low BMD). This highlights the importance of selecting the most 
appropriate initial therapy in patients who are far below the ultimate T-score goal. 
A goal of T-score > -2.5 (or higher if measurement variability is considered) does not apply to 
patients who initiate treatment because of high fracture risk with baseline T-scores > -2.5. A more 
aggressive treatment goal (T-score > -2.0 instead of > -2.5) may be desirable for patients with a very 
high baseline risk of fracture, such as those with a recent vertebral fracture or those over age 70 years 
of age.(49) Applying goal-directed treatment for these patients requires development of methods for 
assessing fracture risk in patients receiving drug treatments.  
Evidence and recommendations regarding the use of BMD for making clinical decisions to 
continue or withhold treatment with alendronate or zoledronic acid and the value of BMD for 
predicting fractures while on treatment are based on femoral neck or total hip BMD. There are no such 
data for lumbar spine BMD or other measurement sites. Nevertheless, including lumbar spine T-score 
as a goal of treatment is consistent with recommendations WKDWWKHGLDJQRVLVRIµRVWHRSRURVLV¶EHPDGH
when the T-VFRUHLV-2.5 at the femoral neck, total hip, or lumbar spine.(7,50) Maintaining treatment 
goals attained with non-bisphosphonate agents requires continuing the agent or switching to a 
bisphosphonate.  Additional data are needed about the relative merits and safety continuing treatment 
or switching to a different agent. . 
There are important caveats to these principles. Clinician judgment and patient preference may 
sometimes override numerical goals.  These proposed recommendations are not intended to describe 
comprehensive care for patients, which should also include regular physical activity, assurance of 
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adequate nutrition, avoidance of smoking and excessive alcohol intake. Patients with a history of falls 
warrant assessment of risk of future falls and, perhaps, a program of fall prevention that includes 
regular weight-bearing exercise.(51) (52) Importantly, the establishment of goals should not be 
interpreted to deny insurance coverage or reimbursement for further treatment if a patient has achieved 
a goal. 
 
Research needs 
The evidence supporting some of the recommendations is limited. The choice of treatments should 
ideally be based on randomized trials that compare alternative strategies.  Further study is needed to 
fully validate the clinical application of all aspects of goal-directed treatment (Table). In particular, 
evidence and analyses are needed to determine levels of risk or T-score that warrant selection of more 
potent agents instead of a first-line bisphosphonate.  We encourage those who sponsor trials of 
therapeutic agents to conduct comparative studies and analyses that would be valuable to defining goals 
of treatment and support choices of initial and follow-up treatment to reach those goals. 
The Working Group recommends that studies be done to compare the probability of reaching a 
T-score goal ZLWKDOWHUQDWLYHWUHDWPHQWVEDVHGRQDSDWLHQW¶V%0'DQGRWKHUFKDUDFWHULVWLFVWKHVH
could be done with existing data from clinical trials. It would be ideal to have trials that compare the 
anti-fracture efficacy of first-line therapies, such as alendronate, to more potent drugs in patients who 
have low probability of reaching a T-score goal. Fracture risk data are needed on the probability of 
achieving T-score JRDOVEDVHGRQWKHSDWLHQW¶VVWDUWLQJT-score and other characteristics. These 
estimates should be generated from previous trials of current treatments in a form that is easy for 
clinicians to use.  
As noted, the evidence for the potential benefit of switching treatment is limited to a few small 
short-term trials.(4,39-44) The Working Group recommends that trials be conducted comparing 
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continuing bisphosphonate therapy versus switching to presumably more potent treatments for patients 
who have not reached a goal, or who continue to have high fracture risk. These trials should continue 
for at least 3 years to provide data about the probability that switching treatment will achieve a T-score 
goal with longer therapy. Ideally trials comparing continuing or switching treatment would have 
sufficient power to determine whether switching reduces the risk of fracture.  
Models to estimate risk of fracture in patients who are receiving treatment are needed; these 
could be developed from existing data from clinical trials of approved drug treatments.  In addition, 
analyses of associations between change in BMD and change in risk of fracture during treatment are 
needed across all trials for vertebral, nonvertebral, and hip fractures and should be done for new 
treatments that have anti-fracture efficacy.  
3DWLHQW¶VYLHZVDERXWWKHYDOXHRIVHWWLQJJRDOVZRXOGEHYDOXDEOH; further studies are needed to 
elucidate these. A recent study suggested that the threshold risk of fractures at which patients report 
they would be willing to take fracture prevention medication is quite variable.(53) Trials should 
FRPSDUHWKHHIIHFWRIVHWWLQJJRDOVWRVWDQGDUGSUDFWLFHRQSDWLHQW¶VSHUVLVWHQFHDQGDGKHUHQFHZLWK
treatments. 
 
Conclusions 
This Working Group interim report supports the potential value of goal-directed treatment and sets out 
several principles to guide this approach to selecting and monitoring treatments.  Some of these general 
principles, such as considering a more potent initial treatment in those with high risk of fracture, use of 
parenteral therapy for persistent non-adherence, measurement of height and vertebral imaging before 
and during treatment, and continuation or intensification of treatment when a vertebral fracture occurs 
on therapy, could be put into practice now. Others, such as estimating the probability of achieving 
goals with specific initial treatments, and deciding, based on risk, to continue or switch agents during 
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treatment, lack evidence or assessment tools.  These principles are based primarily on the judgment of 
experts who comprised the Working Group.  Achievement of treatment goals presented here is not 
possible for all patients due to limited efficacy of medications that are currently available. This may 
change with the development and approval of new agents or combinations of medications that provide 
more robust effects on fracture risk and BMD than current agents. Finally, these preliminary principles 
should be revisited when relevant new data and analyses become available and when new treatments 
with substantially greater effects on BMD and fracture risk are approved. 
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